Possible reduction in indinavir serum concentrations by bosentan.
Beau-Salinas
F
F
Garot
D
D
Le Guellec
C
C
Jonville-Béra
A P
AP
Ingremeau
V
V
Autret-Leca
E
E
D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D019540:Area Under Curve; D000077300:Bosentan; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy; D019469:Indinavir / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008657:Metabolic Clearance Rate; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019469:Indinavir; D000077300:Bosentan